Literature DB >> 7570237

Dust and pneumoconiosis in the South African foundry industry.

D Rees1, R Weiner.   

Abstract

The objectives of this study were to estimate the extent of occupational health monitoring for dust and pneumoconiosis in the foundry industry and to assess dust levels and the prevalence of pneumoconiosis in a group of foundries. In only 13 (16%) of the 82 foundries that responded to a postal questionnaire were regular periodic full-sized chest radiographs done. Dust levels were measured every 3 years or more frequently in 20 foundries (24%). An uncontrolled dust hazard was evident in all 9 foundries surveyed between 1983 and 1992. The prevalence of silicosis ranged from 0% to 10.3% and increased with duration of service. The study provided convincing evidence of neglect of occupational health by the foundry industry.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7570237

Source DB:  PubMed          Journal:  S Afr Med J


  3 in total

1.  Assessment of Occupational Exposure to Dust and Crystalline Silica in Foundries.

Authors:  Ali Omidianidost; Mehdi Ghasemkhani; Mansour R Azari; Farideh Golbabaei
Journal:  Tanaffos       Date:  2015

2.  Inflammatory and coagulatory markers and exposure to different size fractions of particle mass, number and surface area air concentrations in Swedish iron foundries, in particular respirable quartz.

Authors:  Håkan Westberg; Alexander Hedbrant; Alexander Persson; Ing-Liss Bryngelsson; Anders Johansson; Annette Ericsson; Bengt Sjögren; Leo Stockfelt; Eva Särndahl; Lena Andersson
Journal:  Int Arch Occup Environ Health       Date:  2019-06-04       Impact factor: 3.015

3.  Respiratory health and inflammatory markers - Exposure to respirable dust and quartz and chemical binders in Swedish iron foundries.

Authors:  Lena Andersson; Ing-Liss Bryngelsson; Alexander Hedbrant; Alexander Persson; Anders Johansson; Annette Ericsson; Ina Lindell; Leo Stockfelt; Eva Särndahl; Håkan Westberg
Journal:  PLoS One       Date:  2019-11-01       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.